JP2010527922A5 - - Google Patents

Info

Publication number

JP2010527922A5

JP2010527922A5 JP2010507980A JP2010507980A JP2010527922A5 JP 2010527922 A5 JP2010527922 A5 JP 2010527922A5 JP 2010507980 A JP2010507980 A JP 2010507980A JP 2010507980 A JP2010507980 A JP 2010507980A JP 2010527922 A5 JP2010527922 A5 JP 2010527922A5

Authority

JP

Japan

Prior art keywords

btm

contrast agent

group

independently

formula

Prior art date

2008-05-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002872 contrast media Substances 0.000 claims 14
• 108090000765 processed proteins & peptides Proteins 0.000 claims 7
• 125000000217 alkyl group Chemical group 0.000 claims 6
• 125000004181 carboxyalkyl group Chemical group 0.000 claims 4
• 238000001727 in vivo Methods 0.000 claims 4
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 4
• 102000004190 Enzymes Human genes 0.000 claims 3
• 108090000790 Enzymes Proteins 0.000 claims 3
• 150000001413 amino acids Chemical class 0.000 claims 3
• 238000012634 optical imaging Methods 0.000 claims 3
• 239000002202 Polyethylene glycol Substances 0.000 claims 2
• 125000002993 cycloalkylene group Chemical group 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 238000012544 monitoring process Methods 0.000 claims 2
• 229920001223 polyethylene glycol Polymers 0.000 claims 2
• 125000000542 sulfonic acid group Chemical group 0.000 claims 2
• 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
• 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 108091034117 Oligonucleotide Proteins 0.000 claims 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
• 125000003342 alkenyl group Chemical group 0.000 claims 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
• 125000000304 alkynyl group Chemical group 0.000 claims 1
• 239000005557 antagonist Substances 0.000 claims 1
• 125000000732 arylene group Chemical group 0.000 claims 1
• 150000001768 cations Chemical class 0.000 claims 1
• 150000001875 compounds Chemical class 0.000 claims 1
• 230000021615 conjugation Effects 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 238000004090 dissolution Methods 0.000 claims 1
• 239000002532 enzyme inhibitor Substances 0.000 claims 1
• 229940125532 enzyme inhibitor Drugs 0.000 claims 1
• 239000012634 fragment Substances 0.000 claims 1
• 125000000524 functional group Chemical group 0.000 claims 1
• 125000004474 heteroalkylene group Chemical group 0.000 claims 1
• 125000005549 heteroarylene group Chemical group 0.000 claims 1
• 239000012216 imaging agent Substances 0.000 claims 1
• 238000003384 imaging method Methods 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 125000005647 linker group Chemical group 0.000 claims 1
• 230000004807 localization Effects 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000002503 metabolic effect Effects 0.000 claims 1
• 230000004060 metabolic process Effects 0.000 claims 1
• 102000005962 receptors Human genes 0.000 claims 1
• 108020003175 receptors Proteins 0.000 claims 1
• 239000007787 solid Substances 0.000 claims 1
• 239000000758 substrate Substances 0.000 claims 1
• 125000004964 sulfoalkyl group Chemical group 0.000 claims 1
• 230000008685 targeting Effects 0.000 claims 1